tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Memphasys Announces Board Update and Strategic Focus

Story Highlights
Memphasys Announces Board Update and Strategic Focus

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Memphasys Ltd ( (AU:MEM) ) has issued an update.

Memphasys Limited announced the resignation of Mr. Paul Wright as Non-Executive Director, who has been with the company since March 2020, contributing significantly to its progress. The company remains focused on the commercialisation of its Felix™ technology in early access markets, supported by a strong board with expertise in technology, commercialisation, and reproductive health, ensuring continued growth and strategic development.

More about Memphasys Ltd

Memphasys Limited (ASX: MEM) is a biotechnology company specializing in advanced reproductive biotechnology. The company develops medical devices, diagnostics, and proprietary media for human and animal applications, with flagship technologies such as the Felix™ and RoXsta™ Systems aimed at enhancing fertility outcomes worldwide.

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$9.92M

For a thorough assessment of MEM stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1